Amedeo Smart

Free Medical Literature Service

 

Amedeo

Breast Cancer
  Free Subscription

Articles published in
Cancer Lett
    October 2025
  1. YAZDI N, Pourjamal N, Katainen R, Vaananen J, et al
    Drug-tolerant persisting polyploid giant cancer cells mediate resistance to HER2-targeting antibody-drug conjugates.
    Cancer Lett. 2025;630:217900.
    >> Share

    September 2025
  2. TAN C, Lyu H, Ruan S, Wu Y, et al
    Subtype-specific HER3 enrichment in basal-like breast cancer is regulated via the GATA2/GATA3-FOXA1 axis.
    Cancer Lett. 2025 Sep 2:218001. doi: 10.1016/j.canlet.2025.218001.
    >> Share

  3. LIU K, Hoover AR, Sun Y, Valerio TI, et al
    Anti-tumor effects on tumor-infiltrating natural killer cells by localized ablative immunotherapy and immune checkpoint inhibitors: An integrated and comparative study using scRNAseq analysis.
    Cancer Lett. 2025;627:217825.
    >> Share

    August 2025
  4. LI C, Gao T, Zhao Q, Li Z, et al
    Inhibition of CPT1A activates the cGAS/STING pathway to enhance neutrophil-mediated tumor abrogation in triple-negative breast cancer.
    Cancer Lett. 2025;633:217991.
    >> Share

    July 2025
  5. RUPP B, Nagpal N, Thanasiu B, Tuck K, et al
    Multiplex characterization of circulating tumor cells from ductal carcinoma in situ patients suggests early tumor dissemination.
    Cancer Lett. 2025;623:217703.
    >> Share

  6. CAI MY, Yin P, Wang ZW, Huang YZ, et al
    Dual Regulation of FZD1/7 by IGF2BP3 Enhances Stem-like Properties and Carboplatin Resistance in Triple-Negative Breast Cancer.
    Cancer Lett. 2025 Jul 22:217944. doi: 10.1016/j.canlet.2025.217944.
    >> Share

  7. ZHANG M, Tang C, Li S, Jiang X, et al
    NSUN2-mediated m(5)C modification of KDM6B mRNA enhances osteoclast differentiation and promotes breast cancer bone metastasis.
    Cancer Lett. 2025 Jul 19:217939. doi: 10.1016/j.canlet.2025.217939.
    >> Share

  8. WANG SC, Shen YC, Pan MR, Ou-Yang F, et al
    Deglycosylated PD-L1 is a biomarker for immune checkpoint blockade response: a real-world study in breast cancer patients in Taiwan.
    Cancer Lett. 2025 Jul 10:217912. doi: 10.1016/j.canlet.2025.217912.
    >> Share

  9. DI RUSSO S, Borsatti GE, Bouzidi A, Liberati FR, et al
    NF-kappaB-mediated cytokine secretion and glutamate metabolic reprogramming converge in breast cancer brain tropism.
    Cancer Lett. 2025 Jul 8:217907. doi: 10.1016/j.canlet.2025.217907.
    >> Share

  10. TAKAO S, Furumoto H, Furusawa A, Kano M, et al
    Preserved host immunity with intercellular adhesion molecule-1 (ICAM-1)-targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of triple-negative breast cancer and other malignancies.
    Cancer Lett. 2025 Jul 7:217906. doi: 10.1016/j.canlet.2025.217906.
    >> Share

  11. CHICA-PARRADO MR, Kim GM, Uemoto Y, Napolitano F, et al
    Corrigendum to "Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer" [604 (2024) 217219 1-12].
    Cancer Lett. 2025 Jul 5:217891. doi: 10.1016/j.canlet.2025.217891.
    >> Share

    June 2025
  12. HAYKAL MM, Rodrigues-Ferreira S, El Botty R, Sourd L, et al
    Targeting WEE1 kinase as a therapeutic strategy in ATIP3-deficient breast cancers.
    Cancer Lett. 2025;620:217665.
    >> Share

  13. SABIT H, Adel A, Abdelfattah MM, Ramadan RM, et al
    The role of tumor microenvironment and immune cell crosstalk in triple-negative breast cancer (TNBC): Emerging therapeutic opportunities.
    Cancer Lett. 2025;628:217865.
    >> Share

  14. ZHOU W, Ding Q
    Advancing Neoadjuvant Therapy with Inetetamab for HER2-Positive Breast Cancer.
    Cancer Lett. 2025 Jun 5:217852. doi: 10.1016/j.canlet.2025.217852.
    >> Share

    May 2025
  15. WU R, Yu S, Bi A, Li Y, et al
    Therapeutic targeting of circTNK2 with nanoparticles restores tamoxifen sensitivity and enhances NK cell-mediated immunity in ER-positive breast cancer.
    Cancer Lett. 2025 May 24:217823. doi: 10.1016/j.canlet.2025.217823.
    >> Share

  16. ELAYAPILLAI SP, Dogra S, Hladik C, Lausen J, et al
    Preferential Release of microRNAs via Extracellular Vesicles is Associated with Ductal Carcinoma In Situ to Invasive Breast Cancer Progression.
    Cancer Lett. 2025 May 17:217794. doi: 10.1016/j.canlet.2025.217794.
    >> Share

  17. UEMOTO Y, A Lin CC, Wang B, Ye D, et al
    Corrigendum to "Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations" [619 1 (2025) 217668 1-13].
    Cancer Lett. 2025;626:217782.
    >> Share

  18. WALTER V, Koch A, Hillmann D, Dannehl D, et al
    Association of CMV Status with Response to Neoadjuvant Chemoimmunotherapy in Early Triple-Negative Breast Cancer.
    Cancer Lett. 2025 May 10:217789. doi: 10.1016/j.canlet.2025.217789.
    >> Share

  19. ZUO WJ, Ma LX, Wang ZH, Cao XC, et al
    Efficacy and safety of inetetamab plus pertuzumab and nab-paclitaxel as neoadjuvant therapy for HER2+ breast cancer: A single-arm multicenter phase II clinical trial.
    Cancer Lett. 2025 May 10:217785. doi: 10.1016/j.canlet.2025.217785.
    >> Share

  20. LIU S, Chen H, Gagea M, Federico L, et al
    ADAMs contribute to triple negative breast cancer via mTORC1 pathway: targeting ADAM-mTOR axis improves efficacy.
    Cancer Lett. 2025 May 6:217775. doi: 10.1016/j.canlet.2025.217775.
    >> Share

  21. JIANG C, Qian Y, Bai X, Li S, et al
    SLC7A5/E2F1/PTBP1/PKM2 axis mediates progression and therapy effect of triple-negative breast cancer through the crosstalk of amino acid metabolism and glycolysis pathway.
    Cancer Lett. 2025;617:217612.
    >> Share

    April 2025
  22. GRIMSLEY HE, Antczak M, Reddin IG, Weiler N, et al
    Using a novel panel of drug-resistant triple-negative breast cancer cell lines to identify candidate therapeutic targets and biomarkers.
    Cancer Lett. 2025 Apr 27:217754. doi: 10.1016/j.canlet.2025.217754.
    >> Share

  23. XIE Y, Xie J, Huang G, Zhang J, et al
    Isoliquiritigenin reduces brain metastasis by circNAV3-ST6GALNAC5-EGFR axis in triple negative breast cancer.
    Cancer Lett. 2025 Apr 21:217734. doi: 10.1016/j.canlet.2025.217734.
    >> Share

  24. KUNDU M, Greer YE, Lobanov A, Ridnour L, et al
    TRAIL induces cytokine production via the NFkB2 pathway promoting neutrophil chemotaxis and neutrophil-mediated immune-suppression in triple negative breast cancer cells.
    Cancer Lett. 2025;620:217692.
    >> Share

    March 2025
  25. LI H, Chatla S, Liu X, Tian Z, et al
    ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination.
    Cancer Lett. 2025;613:217505.
    >> Share

  26. UEMOTO Y, Lin CA, Wang B, Ye D, et al
    Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations.
    Cancer Lett. 2025;619:217668.
    >> Share

  27. YOU X, Hu X, Sun Z, Xu W, et al
    Dual targeting PPARalpha and NPC1L1 metabolic vulnerabilities blocks tumorigenesis.
    Cancer Lett. 2025;612:217493.
    >> Share

  28. GILON-ZALTSMAN O, Weidenfeld-Barenboim K, Samara H, Feuermann Y, et al
    Targeting dormant disseminated tumor cells and their permissive niche by pro-resolving mediators derived from resolution-phase macrophages.
    Cancer Lett. 2025;612:217468.
    >> Share

    February 2025
  29. ZENG Z, Yi Z, Xu B
    The biological and technical challenges facing utilizing circulating tumor DNA in non-metastatic breast cancer patients.
    Cancer Lett. 2025 Feb 19:217574. doi: 10.1016/j.canlet.2025.217574.
    >> Share

  30. CHEN H, Lin L, Qiao Z, Pei Y, et al
    YTHDF3 drives tumor growth and metastasis by recruiting eIF4B to promote Notch2 translation in breast cancer.
    Cancer Lett. 2025;614:217534.
    >> Share

    January 2025
  31. ZHANG R, Jiang WJ, Zhao S, Kang LJ, et al
    FOXF2 expression triggered by endocrine therapy orchestrates therapeutic resistance through reorganization of chromatin architecture in breast cancer.
    Cancer Lett. 2025 Jan 17:217463. doi: 10.1016/j.canlet.2025.217463.
    >> Share

  32. TAN N, Xia C, Yan X, Cao M, et al
    Extending breast cancer screening beyond age 45-64 years in China: a cost-effectiveness analysis.
    Cancer Lett. 2025 Jan 13:217457. doi: 10.1016/j.canlet.2025.217457.
    >> Share

  33. USAMA M, Hsu YC, Safaei M, Chen CY, et al
    Antibody-drug conjugates targeting SSEA-4 inhibits growth and migration of SSEA-4 positive breast cancer cells.
    Cancer Lett. 2025;611:217453.
    >> Share

  34. WANG Y, Zhou X, Lei Y, Chu Y, et al
    Corrigendum to "NNMT contributes to high metastasis of triple negative breast cancer by enhancing PP2A/MEK/ERK/c-Jun/ABCA1 pathway mediated membrane fluidity"[Cancer Lett. 547 (2022) 215884].
    Cancer Lett. 2025 Jan 3:217424. doi: 10.1016/j.canlet.2024.217424.
    >> Share

    December 2024
  35. JIA Y, Chen Y, Chen M, He M, et al
    Oncogenic HJURP enhancer promotes the aggressive behavior of triple-negative breast cancer in association with p53/E2F1/FOXM1-axis.
    Cancer Lett. 2024 Dec 28:217423. doi: 10.1016/j.canlet.2024.217423.
    >> Share

  36. WANG K, He Q, Jiang X, Wang T, et al
    Targeting UBE2T suppresses breast cancer stemness through CBX6-mediated transcriptional repression of SOX2 and NANOG.
    Cancer Lett. 2024 Dec 21:217409. doi: 10.1016/j.canlet.2024.217409.
    >> Share

    November 2024
  37. MUGHAL MJ, Zhang Y, Li Z, Zhou S, et al
    TFAP2C-DDR1 Axis Regulates Resistance to CDK4/6 Inhibitor in Breast Cancer.
    Cancer Lett. 2024 Nov 25:217356. doi: 10.1016/j.canlet.2024.217356.
    >> Share

  38. GERRATANA L, Davis AA, Foffano L, Reduzzi C, et al
    Integrating Machine Learning-Predicted Circulating Tumor Cells (CTCs) and circulating tumor DNA (ctDNA) in Metastatic Breast Cancer: a proof of principle study on endocrine resistance profiling.
    Cancer Lett. 2024 Nov 20:217325. doi: 10.1016/j.canlet.2024.217325.
    >> Share

  39. LIU K, Hoover AR, Wang L, Sun Y, et al
    Localized ablative immunotherapy enhances antitumor immunity by modulating the transcriptome of tumor-infiltrating Gamma delta T cells.
    Cancer Lett. 2024;604:217267.
    >> Share

    October 2024
  40. BHATTARAI PY, Kim G, Lim SC, Choi HS, et al
    METTL3-STAT5B interaction facilitates the co-transcriptional m(6)A modification of mRNA to promote breast tumorigenesis.
    Cancer Lett. 2024;603:217215.
    >> Share

    September 2024
  41. CHIANG CH, Xu XH, Song J, Xanthavanij N, et al
    The incidence and risk of cardiovascular events associated with pembrolizumab in patients with breast cancer.
    Cancer Lett. 2024 Sep 25:217277. doi: 10.1016/j.canlet.2024.217277.
    >> Share

  42. YU L, Wei W, Lv J, Lu Y, et al
    FABP4-mediated lipid metabolism promotes TNBC progression and breast cancer stem cell activity.
    Cancer Lett. 2024 Sep 19:217271. doi: 10.1016/j.canlet.2024.217271.
    >> Share

  43. WINNARD PT JR, Vesuna F, Bol GM, Gabrielson KL, et al
    Targeting RNA Helicase DDX3X with a Small Molecule Inhibitor for Breast Cancer Bone Metastasis Treatment.
    Cancer Lett. 2024 Sep 19:217260. doi: 10.1016/j.canlet.2024.217260.
    >> Share

  44. LIU X, Ma Z, Jing X, Wang G, et al
    The deubiquitinase OTUD5 stabilizes SLC7A11 to promote progression and reduce paclitaxel sensitivity in triple-negative breast cancer.
    Cancer Lett. 2024 Sep 12:217232. doi: 10.1016/j.canlet.2024.217232.
    >> Share

  45. CHICA-PARRADO MR, Kim GM, Uemoto Y, Napolitano F, et al
    Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer.
    Cancer Lett. 2024 Sep 5:217219. doi: 10.1016/j.canlet.2024.217219.
    >> Share

  46. ZHANG Z, Zhao M, Wang Q, Wang X, et al
    Forkhead box protein FOXK1 disrupts the circadian rhythm to promote breast tumorigenesis in response to insulin resistance.
    Cancer Lett. 2024;599:217147.
    >> Share

    August 2024
  47. SRIVASTAVA P, Jha S, Singh SK, Vyas H, et al
    Protease activated receptor-1 regulates mixed lineage kinase-3 to drive triple-negative breast cancer tumorigenesis.
    Cancer Lett. 2024;603:217200.
    >> Share

  48. MA Y, Zhang H, Shen X, Yang X, et al
    Aptamer functionalized hypoxia-potentiating agent and hypoxia-inducible factor inhibitor combined with hypoxia-activated prodrug for enhanced tumor therapy.
    Cancer Lett. 2024;598:217102.
    >> Share

  49. LIU B, Liu Y, Yang S, Ye J, et al
    Enhanced desmosome assembly driven by acquired high-level desmoglein-2 promotes phenotypic plasticity and endocrine resistance in ER(+) breast cancer.
    Cancer Lett. 2024;600:217179.
    >> Share

  50. GU T, Vasilatos SN, Yin J, Qin Y, et al
    Restoration of TFPI2 by LSD1 Inhibition Suppresses Tumor Progression and Potentiates Antitumor Immunity in Breast Cancer.
    Cancer Lett. 2024 Aug 16:217182. doi: 10.1016/j.canlet.2024.217182.
    >> Share

  51. VIDANA GAMAGE HE, Albright ST, Smith AJ, Farmer R, et al
    Development of NR0B2 as a therapeutic target for the re-education of tumor associated myeloid cells.
    Cancer Lett. 2024;597:217086.
    >> Share

  52. VIDANA GAMAGE HE, Shahoei SH, Wang Y, Jacquin E, et al
    NR0B2 re-educates myeloid immune cells to reduce regulatory T cell expansion and progression of breast and other solid tumors.
    Cancer Lett. 2024;597:217042.
    >> Share

  53. REGUA AT, Bindal S, Najjar MK, Zhuang C, et al
    Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers.
    Cancer Lett. 2024;597:217023.
    >> Share

  54. YANG Y, Hao X, Zhang J, Gao T, et al
    The E3 ligase TRIM22 functions as a tumor suppressor in breast cancer by targeting CCS for proteasomal degradation to inhibit STAT3 signaling.
    Cancer Lett. 2024 Aug 8:217157. doi: 10.1016/j.canlet.2024.217157.
    >> Share

    July 2024
  55. LI M, Zhang L, Guan T, Huang L, et al
    Energy stress-activated AMPK phosphorylates Snail1 and suppresses its stability and oncogenic function.
    Cancer Lett. 2024;595:216987.
    >> Share

  56. LIU Y, Yin S, Lu G, Du Y, et al
    The intersection of the nervous system and breast cancer.
    Cancer Lett. 2024;598:217132.
    >> Share

  57. ZHANG H, Zhang L, He Y, Jiang D, et al
    PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer.
    Cancer Lett. 2024 Jul 8:217112. doi: 10.1016/j.canlet.2024.217112.
    >> Share

  58. PERDRIX ROSELL A, Maiques O, Martin JAJ, Chakravarty P, et al
    Corrigendum to "Early functional mismatch between breast cancer cells and their tumour microenvironment suppresses long term growth" [Cancer Lett. 544 (2022), 215800].
    Cancer Lett. 2024 Jul 1:217078. doi: 10.1016/j.canlet.2024.217078.
    >> Share

    June 2024
  59. WAN YX, Qi XW, Lian YY, Liu ZY, et al
    Electroacupuncture Facilitates Vascular Normalization by Inhibiting Glyoxalase1 in Endothelial Cells to Attenuate Glycolysis and Angiogenesis in Triple-Negative Breast Cancer.
    Cancer Lett. 2024 Jun 28:217094. doi: 10.1016/j.canlet.2024.217094.
    >> Share

  60. YU Y, Cao WM, Cheng F, Shi Z, et al
    FOXK2 amplification promotes breast cancer development and chemoresistance.
    Cancer Lett. 2024 Jun 18:217074. doi: 10.1016/j.canlet.2024.217074.
    >> Share

  61. LIU J, Zhai M, Chen Y, Wei Y, et al
    Acetylation-dependent deubiquitinase USP26 stabilizes BAG3 to promote breast cancer progression.
    Cancer Lett. 2024 Jun 14:217005. doi: 10.1016/j.canlet.2024.217005.
    >> Share

  62. WANG S, Xu L, Wang D, Zhao S, et al
    YTHDF1 promotes the osteolytic bone metastasis of breast cancer via inducing EZH2 and CDH11 translation.
    Cancer Lett. 2024 Jun 11:217047. doi: 10.1016/j.canlet.2024.217047.
    >> Share

  63. LI SY, Zhang N, Zhang H, Wang N, et al
    Deciphering the TCF19/miR-199a-5p/SP1/LOXL2 pathway: Implications for breast cancer metastasis and epithelial-mesenchymal transition.
    Cancer Lett. 2024;597:216995.
    >> Share

  64. ANDRIANI L, Ling YX, Yang SY, Zhao Q, et al
    Sideroflexin-1 promotes progression and sensitivity to lapatinib in triple-negative breast cancer by inhibiting the TOLLIP-mediated autophagic degradation of CIP2A.
    Cancer Lett. 2024 Jun 5:217008. doi: 10.1016/j.canlet.2024.217008.
    >> Share

  65. OLUWALANA D, Adeleye KL, Krutilina RI, Chen H, et al
    Biological activity of a stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor, 60c, in metastatic, triple-negative breast cancer.
    Cancer Lett. 2024 Jun 5:217011. doi: 10.1016/j.canlet.2024.217011.
    >> Share

  66. RIVERA-RAMOS A, Cruz-Hernandez L, Talaveron R, Sanchez-Montero MT, et al
    Galectin-3 depletion tames pro-tumoural microglia and restrains cancer cells growth.
    Cancer Lett. 2024;591:216879.
    >> Share

    May 2024
  67. SONG Y, Ren S, Chen X, Li X, et al
    Inhibition of MFN1 restores tamoxifen-induced apoptosis in resistant cells by disrupting aberrant mitochondrial fusion dynamics.
    Cancer Lett. 2024;590:216847.
    >> Share

  68. LV Y, Sun S, Zhang J, Wang C, et al
    Loss of RBM45 inhibits breast cancer progression by reducing the SUMOylation of IRF7 to promote IFNB1 transcription.
    Cancer Lett. 2024 May 24:216988. doi: 10.1016/j.canlet.2024.216988.
    >> Share

  69. LIN Z, Chen L, Wang Y, Zhang T, et al
    Improving Ultrasound Diagnostic Precision for Breast Cancer and Adenosis with Modality-Specific Enhancement (MSE) - Breast Net.
    Cancer Lett. 2024 May 23:216977. doi: 10.1016/j.canlet.2024.216977.
    >> Share

  70. BELLI S, Esposito D, Ascione CM, Messina F, et al
    EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer.
    Cancer Lett. 2024 May 22:216968. doi: 10.1016/j.canlet.2024.216968.
    >> Share

    April 2024
  71. ZHANG Y, Tan Y, Yuan J, Tang H, et al
    circLIFR-007 reduces liver metastasis via promoting hnRNPA1 nuclear export and YAP phosphorylation in breast cancer.
    Cancer Lett. 2024;592:216907.
    >> Share

  72. WANG J, Fan P, Shen P, Fan C, et al
    XBP1s activates METTL3/METTL14 for ER-phagy and paclitaxel sensitivity regulation in breast cancer.
    Cancer Lett. 2024 Apr 4:216846. doi: 10.1016/j.canlet.2024.216846.
    >> Share

  73. LI K, Lin H, Liu A, Qiu C, et al
    SOD1-high fibroblasts derived exosomal miR-3960 promotes cisplatin resistance in triple-negative breast cancer by suppressing BRSK2-mediated phosphorylation of PIMREG.
    Cancer Lett. 2024;590:216842.
    >> Share

  74. ORHAN E, Velazquez C, Tabet I, Fenou L, et al
    CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer.
    Cancer Lett. 2024 Apr 2:216820. doi: 10.1016/j.canlet.2024.216820.
    >> Share

  75. BULLOCK KK, Shattuck-Brandt R, Scalise C, Luo W, et al
    Endogenous pAKT activity is associated with response to AKT inhibition alone and in combination with immune checkpoint inhibition in murine models of TNBC.
    Cancer Lett. 2024;586:216681.
    >> Share

    March 2024
  76. YANG Z, Chen H, Yin S, Mo H, et al
    PGR-KITLG signaling drives a tumor-mast cell regulatory feedback to modulate apoptosis of breast cancer cells.
    Cancer Lett. 2024 Mar 29:216795. doi: 10.1016/j.canlet.2024.216795.
    >> Share

  77. JABBARZADEH KABOLI P, Chen HF, Babaeizad A, Roustai Geraylow K, et al
    Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer.
    Cancer Lett. 2024 Mar 8:216780. doi: 10.1016/j.canlet.2024.216780.
    >> Share

  78. MADORSKY ROWDO FP, Xiao G, Khramtsova GF, Nguyen J, et al
    Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
    Cancer Lett. 2024;584:216608.
    >> Share

    February 2024
  79. WANG X, Deng X, Hu J, Zheng W, et al
    K48-linked deubiquitination of VGLL4 by USP15 enhances the efficacy of tumor immunotherapy in triple-negative breast cancer.
    Cancer Lett. 2024 Feb 29:216764. doi: 10.1016/j.canlet.2024.216764.
    >> Share

  80. SUN J, Du R, Li X, Liu C, et al
    CD63(+) cancer-associated fibroblasts confer CDK4/6 inhibitor resistance to breast cancer cells by exosomal miR-20.
    Cancer Lett. 2024 Feb 23:216747. doi: 10.1016/j.canlet.2024.216747.
    >> Share

  81. HAN BY, Chen C, Luo H, Lin CJ, et al
    Clinical sequencing defines the somatic and germline mutation landscapes of Chinese HER2-Low Breast Cancer.
    Cancer Lett. 2024 Feb 23:216763. doi: 10.1016/j.canlet.2024.216763.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016